Post-treatment urinary sarcosine as a predictor of recurrent relapses in patients with prostate cancer

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F62156489%3A43210%2F18%3A43914521" target="_blank" >RIV/62156489:43210/18:43914521 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/18:00104807 RIV/00216305:26620/18:PU130367 RIV/65269705:_____/18:00069248

Výsledek na webu

<a href="https://onlinelibrary.wiley.com/doi/10.1002/cam4.1767" target="_blank" >https://onlinelibrary.wiley.com/doi/10.1002/cam4.1767</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1002/cam4.1767" target="_blank" >10.1002/cam4.1767</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Post-treatment urinary sarcosine as a predictor of recurrent relapses in patients with prostate cancer

Popis výsledku v původním jazyce

To date, there has been no evidence regarding the association between urinary sarcosine content and prostate cancer survival. Our main objective was to investigate whether levels of post-treatment urinary sarcosine are associated with relapse. The inclusion criteria were (in accordance with EAU 2017) as follows: histopathologically verified adenocarcinoma in prostate biopsy cores or specimens from transurethral resection of the prostate (TURP) or prostatectomy for benign prostatic enlargement (BPE) with retained ability to urinate. The median follow-up was 53 months. In the study, we retrospectively evaluated a cohort of 511 patients with prostate cancer with various risk factors and treatment strategies. Post-treatment sarcosine levels were elevated in 266 (52%) patients and highly elevated (&gt;= 200 nmol/L) in 71 (13%) patients. Urinary sarcosine content was significantly associated with number of relapses that patients experienced, P = 0.002 for sarcosine &gt;= 200 vs &lt;= 30 nmol/L. Multivariate analysis revealed that sarcosine was an independent predictor of recurrent relapses (&gt;= 2 relapses with an intermediate period of remission), HR = 3.89 (95% CI 1.29-11.7) for sarcosine &gt;200 vs &lt;30 nmol/L. This trend was even more pronounced in a subgroup of patients who underwent radical prostatectomy, HR = 3.29 (95% CI 1.06-10.18), where (single) relapse-free survival could also be predicted by sarcosine levels, HR = 1.96 (1.05-3.66). Urinary sarcosine may become a possible predictor for patients&apos; outcomes, because patients with elevated post-treatment sarcosine could be predicted to have recurrent relapses of the disease.

Název v anglickém jazyce

Post-treatment urinary sarcosine as a predictor of recurrent relapses in patients with prostate cancer

Popis výsledku anglicky

To date, there has been no evidence regarding the association between urinary sarcosine content and prostate cancer survival. Our main objective was to investigate whether levels of post-treatment urinary sarcosine are associated with relapse. The inclusion criteria were (in accordance with EAU 2017) as follows: histopathologically verified adenocarcinoma in prostate biopsy cores or specimens from transurethral resection of the prostate (TURP) or prostatectomy for benign prostatic enlargement (BPE) with retained ability to urinate. The median follow-up was 53 months. In the study, we retrospectively evaluated a cohort of 511 patients with prostate cancer with various risk factors and treatment strategies. Post-treatment sarcosine levels were elevated in 266 (52%) patients and highly elevated (&gt;= 200 nmol/L) in 71 (13%) patients. Urinary sarcosine content was significantly associated with number of relapses that patients experienced, P = 0.002 for sarcosine &gt;= 200 vs &lt;= 30 nmol/L. Multivariate analysis revealed that sarcosine was an independent predictor of recurrent relapses (&gt;= 2 relapses with an intermediate period of remission), HR = 3.89 (95% CI 1.29-11.7) for sarcosine &gt;200 vs &lt;30 nmol/L. This trend was even more pronounced in a subgroup of patients who underwent radical prostatectomy, HR = 3.29 (95% CI 1.06-10.18), where (single) relapse-free survival could also be predicted by sarcosine levels, HR = 1.96 (1.05-3.66). Urinary sarcosine may become a possible predictor for patients&apos; outcomes, because patients with elevated post-treatment sarcosine could be predicted to have recurrent relapses of the disease.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Cancer Medicine

ISSN

2045-7634

e-ISSN

—

Svazek periodika

7

Číslo periodika v rámci svazku

11

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

9

Strana od-do

5411-5419

Kód UT WoS článku

000450673300009

EID výsledku v databázi Scopus

2-s2.0-85053412183